FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1485432800> ?p ?o ?g. }

• W1485432800 endingPage "5" @default.
• W1485432800 startingPage "4091" @default.
• W1485432800 abstract "The therapeutic options for the treatment of androgen-independent prostatic cancers are rather limited; this is mainly because our understanding of the local mechanisms involved in the control of androgen-independent proliferation of the tumor is still very poor. The present experiments have been performed to verify whether luteinizing hormone-releasing hormone (LHRH) agonists may possess a direct effect on the growth of the human androgen-independent prostate cancer cells DU 145 and whether a LHRH growth regulatory system may be present in these cells. The data have shown that two potent LHRH agonists (Zoladex and Buserelin) exert a significant and dose-dependent antiproliferative action on DU 145 cells, after 4 days of treatment. The inhibitory action of Zoladex and Buserelin is completely counteracted by the simultaneous treatment of the cells with a potent LHRH antagonist, suggesting that the action of the LHRH agonists may be mediated by specific receptors. This hypothesis has been confirmed by the demonstration that low-affinity binding sites for 125I-Buserelin are present on DU 145 cell membranes, particularly when cells are cultured in serum-free conditions. By using the reverse transcription-polymerase chain reaction technique, in the presence of a pair of specific oligonucleotide primers complementary to the human LHRH complementary DNA, it has been demonstrated that a mRNA for LHRH is expressed in DU 145 cells. Taken together, these data seem to indicate that an autocrine/paracrine LHRH (or LHRH-like) loop is present in androgen-independent prostate cancer cells, and may participate in the regulation of tumor cell growth. To verify this hypothesis, DU 145 cells have been cultured in serum-free conditions, and treated with a LHRH antagonist for 4 days. The treatment resulted in a significant increase of cell proliferation, suggesting an inhibitory role for the LHRH system in the local regulation of cell growth. In conclusion, these data demonstrate that: (a) LHRH agonists exert a specific antiproliferative action on the human androgen-independent DU 145 cells; (b) an autocrine/paracrine LHRH (or LHRH-like) loop, which seems to be inhibitory on cell proliferation, is expressed in DU 145 cells." @default.
• W1485432800 created "2016-06-24" @default.
• W1485432800 creator A5026037422 @default.
• W1485432800 creator A5043408864 @default.
• W1485432800 creator A5050634599 @default.
• W1485432800 creator A5072925905 @default.
• W1485432800 creator A5081336487 @default.
• W1485432800 creator A5084616421 @default.
• W1485432800 date "1994-08-01" @default.
• W1485432800 modified "2023-09-29" @default.
• W1485432800 title "Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop." @default.
• W1485432800 cites W1972073966 @default.
• W1485432800 cites W2008061301 @default.
• W1485432800 cites W2009981615 @default.
• W1485432800 cites W2012757283 @default.
• W1485432800 cites W2016514222 @default.
• W1485432800 cites W2032413102 @default.
• W1485432800 cites W2043813981 @default.
• W1485432800 cites W2051917498 @default.
• W1485432800 cites W2054045654 @default.
• W1485432800 cites W2058901607 @default.
• W1485432800 cites W2067808043 @default.
• W1485432800 cites W2078230286 @default.
• W1485432800 cites W2089639796 @default.
• W1485432800 cites W2117999383 @default.
• W1485432800 cites W2128635872 @default.
• W1485432800 cites W2137330819 @default.
• W1485432800 cites W2138209396 @default.
• W1485432800 cites W2147405625 @default.
• W1485432800 cites W2405180392 @default.
• W1485432800 cites W2410342715 @default.
• W1485432800 cites W2423950142 @default.
• W1485432800 cites W2437222008 @default.
• W1485432800 cites W2442956053 @default.
• W1485432800 cites W2606708 @default.
• W1485432800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8033142" @default.
• W1485432800 hasPublicationYear "1994" @default.
• W1485432800 type Work @default.
• W1485432800 sameAs 1485432800 @default.
• W1485432800 citedByCount "55" @default.
• W1485432800 countsByYear W14854328002014 @default.
• W1485432800 countsByYear W14854328002015 @default.
• W1485432800 countsByYear W14854328002017 @default.
• W1485432800 countsByYear W14854328002019 @default.
• W1485432800 countsByYear W14854328002020 @default.
• W1485432800 countsByYear W14854328002022 @default.
• W1485432800 countsByYear W14854328002023 @default.
• W1485432800 crossrefType "journal-article" @default.
• W1485432800 hasAuthorship W1485432800A5026037422 @default.
• W1485432800 hasAuthorship W1485432800A5043408864 @default.
• W1485432800 hasAuthorship W1485432800A5050634599 @default.
• W1485432800 hasAuthorship W1485432800A5072925905 @default.
• W1485432800 hasAuthorship W1485432800A5081336487 @default.
• W1485432800 hasAuthorship W1485432800A5084616421 @default.
• W1485432800 hasConcept C121608353 @default.
• W1485432800 hasConcept C126322002 @default.
• W1485432800 hasConcept C128240485 @default.
• W1485432800 hasConcept C134018914 @default.
• W1485432800 hasConcept C170493617 @default.
• W1485432800 hasConcept C2777230143 @default.
• W1485432800 hasConcept C2777911890 @default.
• W1485432800 hasConcept C2778575703 @default.
• W1485432800 hasConcept C2778894405 @default.
• W1485432800 hasConcept C2778938600 @default.
• W1485432800 hasConcept C2780192828 @default.
• W1485432800 hasConcept C502942594 @default.
• W1485432800 hasConcept C71315377 @default.
• W1485432800 hasConcept C71924100 @default.
• W1485432800 hasConcept C7876069 @default.
• W1485432800 hasConcept C86803240 @default.
• W1485432800 hasConceptScore W1485432800C121608353 @default.
• W1485432800 hasConceptScore W1485432800C126322002 @default.
• W1485432800 hasConceptScore W1485432800C128240485 @default.
• W1485432800 hasConceptScore W1485432800C134018914 @default.
• W1485432800 hasConceptScore W1485432800C170493617 @default.
• W1485432800 hasConceptScore W1485432800C2777230143 @default.
• W1485432800 hasConceptScore W1485432800C2777911890 @default.
• W1485432800 hasConceptScore W1485432800C2778575703 @default.
• W1485432800 hasConceptScore W1485432800C2778894405 @default.
• W1485432800 hasConceptScore W1485432800C2778938600 @default.
• W1485432800 hasConceptScore W1485432800C2780192828 @default.
• W1485432800 hasConceptScore W1485432800C502942594 @default.
• W1485432800 hasConceptScore W1485432800C71315377 @default.
• W1485432800 hasConceptScore W1485432800C71924100 @default.
• W1485432800 hasConceptScore W1485432800C7876069 @default.
• W1485432800 hasConceptScore W1485432800C86803240 @default.
• W1485432800 hasIssue "15" @default.
• W1485432800 hasLocation W14854328001 @default.
• W1485432800 hasOpenAccess W1485432800 @default.
• W1485432800 hasPrimaryLocation W14854328001 @default.
• W1485432800 hasRelatedWork W1974613227 @default.
• W1485432800 hasRelatedWork W1995920009 @default.
• W1485432800 hasRelatedWork W2010299757 @default.
• W1485432800 hasRelatedWork W2054508315 @default.
• W1485432800 hasRelatedWork W2061466636 @default.
• W1485432800 hasRelatedWork W2081257388 @default.
• W1485432800 hasRelatedWork W2088987832 @default.
• W1485432800 hasRelatedWork W2089211374 @default.

• next